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Neurobiology of Disease
Soluble Conformers of A and Tau Alter Selective Proteins
Governing Axonal Transport
XMathew A. Sherman,1,2,3Michael LaCroix,1,2,3* Fatou Amar,1,2,3* Megan E. Larson,1,2,3 XColleen Forster,2
XAdriano Aguzzi,4David A. Bennett,5Martin Ramsden,2 and XSylvain E. Lesne´1,2,3
1Department of Neuroscience, 2N. Bud Grossman Center for Memory Research and Care, 3Institute for Translational Neuroscience, University of
Minnesota, Minneapolis, Minnesota 55414, 4Institute of Neuropathology, University Hospital of Zurich, Zurich 8091, Switzerland, and 5Rush Alzheimer
Disease Center, Rush University Medical Center, Chicago, Illinois 60612
Despite the demonstration that amyloid- (A) can trigger increased tauphosphorylation andneurofibrillary tangle (NFT) formation in
vivo, the molecular link associating A and tau pathologies remains ill defined. Here, we observed that exposure of cultured primary
neurons to A trimers isolated from brain tissue of subjects with Alzheimer’s disease led to a specific conformational change of tau
detected by the antibody Alz50. A similar association was supported by postmortem human brain analyses. To study the role of A
trimers in vivo, we created a novel bigenic Tg-ATau mouse line by crossing Tg2576 (Tg-A) and rTg4510 (Tg-Tau) mice. Before
neurodegeneration and amyloidosis, apparent A trimers were increased by 2-fold in 3-month-old Tg-A and Tg-ATau mice
compared with younger mice, whereas soluble monomeric A levels were unchanged. Under these conditions, the expression of sol-
ubleAlz50-tau conformers roseby2.2-fold in the forebrains ofTg-ATaumice comparedwithnontransgenic littermates. Inparallel,
APP accumulated intracellularly, suggestive of a putative dysfunction of anterograde axonal transport. We found that the protein
abundance of the kinesin-1 light chain (KLC1) was reduced selectively in vivo and in vitro when soluble A trimers/Alz50-tau were
present. Importantly, the reduction in KLC1 was prevented by the intraneuronal delivery of Alz50 antibodies. Collectively, our findings
reveal that specific soluble conformers of A and tau cooperatively disrupt axonal transport independently from plaques and tangles.
Finally, these results suggest that not all endogenous A oligomers trigger the same deleterious changes and that the role of each
assembly should be considered separately.
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Introduction
In our current understanding of the physiopathology of Alzhei-
mer’s disease (AD), the soluble forms of the amyloid- peptide
(A) and the microtubule-associated protein tau have been pro-
posed to bemore important than the fibrillar aggregates that have
classically characterized this disorder (Walsh et al., 2002; Cleary
et al., 2005; Santacruz et al., 2005; Lesne´ et al., 2006; Berger et al.,
2007; Roberson et al., 2007; Shankar et al., 2008). Despite the
seminal demonstrations that A exposure can lead to increasedReceived May 31, 2016; revised July 19, 2016; accepted July 31, 2016.
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Significance Statement
Themechanistic link between amyloid- (A) and tau, the twomajor proteins composing the neuropathological lesions detected
in brain tissue ofAlzheimer’s disease subjects, remains unclear.Here, we report that the trimericA species induce a pathological
modification of tau in cultured neurons and in bigenic mice expressing A and human tau. This linkage was also observed in
postmortem brain tissue from subjects with mild cognitive impairment, when A trimers are abundant. Further, this modifica-
tion of tau was associated with the intracellular accumulation of the precursor protein of A, APP, as a result of the selective
decrease in kinesin light chain 1 expression. Our findings suggest that A trimers might cause axonal transport deficits in AD.
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tau phosphorylation and neurofibrillary tangle (NFT) formation
in animals (Go¨tz et al., 2001; Lewis et al., 2001; Oddo et al., 2003),
the exact molecular mechanisms associating A and tau remain
poorly understood (Attems et al., 2011; Larson and Lesne´, 2012;
Lesne´, 2013).
Due to the inherent biology of neuronal cells, axonal transport
is critical for neuronal function and survival. Multiple neurode-
generative disorders, including AD, present with alterations of
fast axonal transport, which have been proposed to represent an
early pathological event (Goldstein, 2001; Stokin et al., 2005; Itt-
ner et al., 2009; Morfini et al., 2009; Muresan and Muresan,
2009). Soluble assemblies of A, also calledAoligomers (oAs),
have been shown to be capable of inhibiting axonal transport in
cultured cells (Rui et al., 2006; Pigino et al., 2009). Additional
reports refined this concept by demonstrating that oligomeric
mixtures of synthetic A disrupt axonal transport in vitro
(Decker et al., 2010; Vossel et al., 2010; Vossel et al., 2015).
In addition to A, tau is known to be concentrated preferen-
tially in axons, where it stabilizes microtubules that serve as
tracks for the transport of organelles, vesicles, and proteins
(Hirokawa and Takemura, 2005) and has been proposed to
induce neuronal cell death by interfering with microtubule-
dependent axonal transport (Stamer et al., 2002). Despite con-
vincing observations showing that tau alters axonal transport
in vitro (Ebneth et al., 1998; Dixit et al., 2008), it is less clear
whether tau acts similarly in vivo (Yuan et al., 2008). Recent
studies indicated that, although tau did not appear to affect
axonal transport under baseline conditions, tau protein levels
were critical for axonal transport in the presence of synthetic
A oligomers (Vossel et al., 2010).
While assessing the effects of purified forms of endogenous
oAs on tau posttranslational modifications, we found that
AD-brain-derived A trimers applied onto primary neurons at
single-digit nanomolar concentrations induced a selective con-
formation change of tau detected by the antibody Alz50 (Carmel
et al., 1996). Supporting this in vitro finding, we found that pro-
tein levels of A trimers, described previously to peak in the brain
tissues of Religious Orders Study (ROS) participants with mild
cognitive impairment (MCI) (Lesne´ et al., 2013), were positively
correlated with soluble Alz50-tau levels. Upon characterizing the
newly created bigenic Tg-ATau mouse model overexpressing
the human APP and human tau, we observed that soluble A
trimers increased independently of monomeric A levels before
neurodegeneration and amyloidosis in the forebrains of these
mice. In associationwith the rise in A trimers observed in young
bigenic mice, soluble Alz50-positive tau levels were also elevated,
whereas other pathological forms of tauwere not. In parallel, APP
accumulated intracellularly in brain tissue of bigenic mice, sug-
gesting possible axonal transport defects. When analyzing puta-
tive modulations in the abundance of proteins governing axonal
transport, the protein expression of the light chain of kinesin-1
(KLC1) was lowered markedly, whereas other motor proteins
appeared to be unaffected. To evaluate the potential effects of A
trimers on proteins regulating axonal transport, we exposed pri-
mary cultured neurons to purified A species. These conditions
recapitulated the selective changes in KLC1 observed in vivo, in-
dicating that A trimers are a potent disruptor of KLC1 expres-
sion in neurons. Finally, we showed that this effect was not
dependent on the expression of the cellular form of the prion
protein PrPC, but did require the presence of tau gene expression
and Alz50-tau conformers.
Materials andMethods
Transgenic mice
Mice from the APP line Tg2576 (MGI_2385631), which express the human
APP with the Swedish mutation (APPKM670/671NL) directed by the hamster
prionproteinpromoter (Hsiao et al., 1996),were crossedwith rTg4510mice
(MGI_4819866) (Ramsden et al., 2005; Santacruz et al., 2005) overexpress-
ing the P301L mutant of four-repeat tau lacking the N-terminal sequences
4R0N (tauP301L). Both lines were kindly provided by Dr. Karen Ashe (Uni-
versity ofMinnesota). Briefly, Tg4510 responders (FVB/N)werematedwith
CKTTA activators (129S6) to generate FVB129S6F1-rTg4510 mice.
rTg4510/mice were subsequently mated with Tg2576 (129S6) to gener-
ate mixed-background mice (129S6)FVB129S6F1-rTg4510xTg2576//.
Dr.AdrianoAguzzi (UniversityHospital ofZurich, Switzerland)kindlypro-
vided Prnp-null mice (MGI_1888773) (Bu¨eler et al., 1992). Htau
(MGI_3057129) (Andorfer et al., 2003) andMapt-null mice (Tucker et al.,
2001)were purchased fromJacksonLaboratories. All experiments described
herewere conducted in full accordancewithAssociation forAssessment and
Accreditation of Lab Animal Care and Institutional Animal Care and Use
Committee guidelines, with every effort made to minimize the number of
mice used. Bothmale and female mice were used in all experiments. Exper-
imenters were kept blinded to the genotype of the animal groups until raw
data were obtained.
Primary cell cultures
Mouse cortical cultures of neurons were prepared from 14- to 15 d-old
embryos as described previously (Lesne´ et al., 2005; Larson et al., 2012)
using 5  105 cells/dish. After 3 d in vitro (DIV), neurons were treated
with 10 M cytosine -D-arabinofuranoside (AraC) to inhibit prolifera-
tion of non-neuronal cells. All experiments were performed on nearly
pure neuronal cultures (98% of microtubule associated protein-2 im-
munoreactive cells) after 12–14 DIV. Six to eight 35 mm dishes per
culture per condition were used across three independent experiments.
Protein extractions
For analyzing A species, two extractions protocols described previ-
ously were used (Lesne´ et al., 2006; Shankar et al., 2008; Sherman and
Lesne´, 2011). In particular, membrane-enriched protein extracts (MB
extracts) refer to protein lysates obtained after the third step of a serial
extraction with a lysis RIPA buffer comprised of 50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, 3% SDS, and 1%
deoxycholate. As detailed in a methodology chapter published re-
cently (Sherman and Lesne´, 2011), samples were then centrifuged at
16,100 g for 90 min. Supernatants were collected and pellets further
extracted with formic acid to analyze fibrillar/deposited proteins. It is
possible that the use of the RIPA lysis buffer might strip loosely bound
A from plaques.
Protein amounts were determined by the Bradford protein assay
(BCA Protein Assay, Pierce). All supernatants were ultracentrifuged
for 60 min at 100,000  g. Finally, before analysis, fractions with
endogenous immunoglobulins were depleted by incubating extracts
sequentially for 1 h at room temperature with 50 l of Protein
A-Sepharose, Fast Flow followed by 50 l of Protein G-Sepharose,
Fast Flow (GE Healthcare Life Sciences).
Purification of human A oligomers from AD brain tissue
Human brain tissue came from participants in the ROS who died with
MCI. Details of the study have been described previously (Bennett et
al., 2012). The study was approved by the Institutional Review Board
or Rush University Medical Center and all subjects signed informed
consent and an Anatomic Gift Act. Soluble oligomeric A species
were purified from AD brain tissue, as reported previously by our
group (Larson et al., 2012). Relative amounts of purified oligomeric
A were calculated based on synthetic A1-42 standards (0.001, 0.025,
0.05, 0.1, 0.25, 0.5, 1.0, and 2.5 ng; Sigma-Aldrich) run alongside the
samples used for experiments.
Western blotting and quantification
SDS-PAGE. Electrophoreses were done on precast 10–20% polyacryl-
amide Tris-Tricine gels and 10.5–14% and 4–10.5% Tris-HCl gels (Bio-
Rad). Protein levels were normalized to 2–100 g of protein per sample
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(depending on targeted protein) and resuspended with 4 Tricine load-
ing buffer before boiling (5 min at 95°C with agitation at 1250 rpm).
Transfer. Thereafter, proteins were transferred to 0.2 m nitrocellu-
lose membrane (Bio-Rad).
Blotting. Nitrocellulose membranes were boiled in 50 ml of PBS by
microwaving for 25 and 15 s with a 3 min interval. Membranes were
blocked in TTBS (Tris-buffered saline plus 0.1% Tween 20) containing
5% bovine serum albumin (BSA) (Sigma-Aldrich) for 1–2 h at room
temperature, and probed with appropriate antisera/antibodies diluted in
5% BSA-TTBS. Primary antibodies were probed either with anti-IgG
immunoglobulins conjugated with biotin or InfraRed dyes (Li-Cor
Biosciences). When biotin-conjugated secondary antibodies were used,
IR-conjugated Neutravidin (Pierce) was added to amplify the signal.
Blots were revealed on an Odyssey platform (Li-Cor Biosciences).
Stripping. When required, membranes were stripped using Restore
Plus Stripping buffer (Pierce) for 30–180 min at room temperature de-
pending on antibody affinity.
Quantification. Densitometry analyses were performed using Opti-
Quant (Packard Bioscience) or Odyssey (Li-Cor) software. Each protein
of interest was probed in three individual experiments under the same
conditions and quantified by software analysis after determination of
experimental conditions ascertaining linearity in the detection of the
signal and are expressed as density light units (DLUs). The method used
allows for a dynamic range of100-fold above background (0.01 106
DLUs). Respective averages were then determined across the triplicate
Western blots.Normalizationwas performed against the neuron-specific
nuclear protein NeuN, also performed in triplicate. None of the protein
brain levels measured correlated with postmortem interval, arguing
against potential protein degradation within human tissues (data not
shown).
Immunoprecipitations
Aliquots (200 g) of protein extracts were diluted to 1 ml with dilution
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl) and incubated with the
appropriate antibodies (5 g of 6E10 or Mab2.1.3/13.1.1 antibodies)
overnight at 4°C. Then, 50l of Protein G-Sepharose, Fast Flow (GE Life
Sciences) 1:1 (v:v) slurry solution with dilution buffer (50 mM Tris-HCl,
pH 7.4, 150mMNaCl, pH 7.4) was added for 2 h. The beads were washed
twice in 1 ml of dilution buffer and proteins eluted in 25 l of loading
SDS-PAGE buffer by boiling.
Antibodies
The following primary antibodies were used in this study: 6E10 (1:2500;
BioLegend catalog #803003, RRID: AB_10175145) and 4G8 (1:2500; Bio
Legendcatalog#800703,RRID:AB_662812),biotinylated-6E10(1:2500;Bio
Legend catalog #803009, RRID: AB_10175146), 22C11 (1:2000; Millipore
catalog #MAB348, RRID:AB_94882), Tau5 (1:2000; BioLegend catalog
#806403,RRID:AB_10175718),Alz50 (1:2000; kind gifts fromPeterDavies,
Albert Einstein College of Medicine), 40-/42-end specific Mab2.1.3 and
Mab13.1.1 (1:1000; kind gifts from Pritam Das, Mayo Jacksonville), anti-
NeuN (1:5000; Millipore catalog #MAB377B, RRID:AB_177621), anti-
MAP2 (1:500; Novus catalog #NB300–213, RRID:AB_2138178),
anti-KLC-1 (1:1000; Millipore catalog #MAB1616, RRID:AB_94286 and
Santa Cruz Biotechnology catalog #sc-25735, RRID:AB_2280879), anti-
kinesin superfamily protein 5 (anti-KIF-5) (1:1000; Abcam catalog
#ab62104, RRID:AB_2249625), anti-JNK-interacting protein 1 (anti-JIP-1)
(1:1000; Abcam catalog #ab24449, RRID:AB_448056 and Abcam catalog
#ab78948, RRID:AB_1640605), anti-Dynein (1:2000; Abcam catalog
#ab75214, RRID:AB_1280872), anti-EB-3 (1:2000; Abcam cata-
log #ab99287, RRID:AB_10676513), anti-Actin (1:10,000;Millipore catalog
#MAB1501, RRID:AB_2223041 and Sigma-Aldrich catalog #A2066, RRID:
Figure 1. Application of soluble A species purified from AD brain tissues induces selective tau pathological changes in mouse primary cortical neurons. A, Protein levels of tau
conformers detected with Alz50 (Alz50-Tau) and total tau as assessed by Western blot using Alz50 and Tau5 antibodies in wild-type primary neurons exposed to human-brain-purified
oligomeric A (1 nM for 1 h). Actin was used as an internal control. B, Quantitation of the modified tau/total tau ratios across conditions revealed a significant conformational change of
tau after exposure to A trimers (lanes 7 and 8). This effect was not detected in neurons treated with soluble A monomers or dimers. Error bars indicate mean  SD, ANOVA
(F(3, 25) 281.604, p 0.0001) followed by Student’s t test,p 0.05, n 6 – 8/treatment). C,D, Influence of sample denaturation on Alz50 immunoreactivity usingWestern blotting
(C, D). Alz50-NS corresponds to the nonspecific25 kDa band detected by Alz50. D, After quantitation of the Western blot data, two-way ANOVA (F(3, 23) 57.2621, p 0.0001)
revealed a significant effect of the genotype (F(1, 23) 170.766, p 0.0001), but no effect of the treatment (F(1, 23) 1.017, p 0.3427) and no genotype*treatment interaction (F(1,
23) 0.002, p 0.961). Error bars indicate the mean SD; n 6/genotype/condition.
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AB_476693), andanti--tubulin (1:100,000; Sigma-Aldrich catalog#T6074,
RRID:AB_477582).
Statistical analyses
When variables were non-normally distributed, nonparametric sta-
tistics were used (Spearman’s rho correlation coefficients, Kruskal–
Wallis nonparametric ANOVA followed by Bonferroni-corrected
two-group post hoc Mann–Whitney U tests). When variables were
normally distributed, the following parametric statistics were used
(one/two-way ANOVA followed by Bonferroni-corrected two-group
post hoc Student’s t tests). Sample size was determined by power
analysis to be able to detect statistically significant changes within a
20% variation of measured responses. Analyses were performed using
JMP 11 or JMP12 (SAS Institute).
Results
Endogenous A trimers induce distinct tau pathological
changes in vitro
We reported previously that A dimers and trimers purified
from AD brain tissue applied at low nanomolar concentrations
induce the hyperphosphorylation of tau at tyrosine 18 (Y18) me-
diated by the Src kinase Fyn inmouse cortical neurons (Larson et
al., 2012). To determine whether other disease-relevant taumod-
ifications were triggered under these conditions by these low-
molecular-weight A oligomers, we used a panel of well
characterized antibodies, includingCP13, PHF1, PG5, andAlz50,
that detect either phosphorylation at serine residues 202 (S202),
396/404 (S396/404), and 409 (S409) or aberrant misfolding of
tau, respectively (Fig. 1) Although tau was hyperphosphory-
lated at Y18 by purified A dimers and trimers, no apparent
enhanced phosphorylation at S202, S396/404, and S409 was
observed compared with cells treated with vehicle or mono-
meric A (data not shown). However, we observed a 3.2-fold
increase in Alz50 immunoreactivity in neurons exposed to A
trimers compared with control cells (Fig. 1A,B). Applying
equimolar concentrations of monomeric or dimeric A did
not trigger such a change. Because the epitope for Alz50 was
reported to be sensitive to denaturation (Carmel et al., 1996),
we compared the detection of Alz50-tau molecules in 12-
month-old Htau mice (Andorfer et al., 2003) and MAPT	 /	
mice (Tucker et al., 2001). Half of the samples were denatured
by boiling before loading onto PAGE gels and the other half
were not subjected to heat denaturation. Using Western blot-
ting, we did not observe differences in the ability to detect
Alz50-tau in Htau mice due to sample denaturation (Fig.
1C,D). The sample denaturation step led to the detection of a
prominent nonspecific 25 kDa band by Alz50 antibodies in
all specimens, including age-matched mouse MAPT	 /	 lit-
termates (Fig. 1C). These results would therefore argue that
heat denaturation does not prevent the accurate detection of
Alz50-positive tau conformers by Western blot. Overall, these
Figure2. Soluble A trimers levels are positively correlated to soluble Alz50-tau conformers in the inferior temporal gyrus of individuals diagnosedwithMCI in the ROS cohort.A, Representative
Western blot images for A and tau proteins in a subset of ROS study participants (9 out of 84). A levels weremeasured following immunoprecipitation using 6E10 (top insert) or amixture of 40-
and 42-end specific antibodies (middle insert). 4G8, 6E10, Tau5, and Alz50 antibodies were used for Western blotting detection. Actin was used as control. B–D, Regression analyses between
low-molecular-weight soluble A species and soluble Alz50-tau conformers in ROSMCImeasured (Spearman’s rho correlation, n 34). The arbitrary units for A and tau protein levels are on the
same scale and correspond to10 6 densitometry light units, as reported in Lesne´ et al. (2013).
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Figure 3. Tissue atrophy and survival rates in Tg-TauAmice. A, Representative images show brain tissue from 13-month-old mice (top, aerial view; bottom, cross-sectional view).
B, Mean weights of whole-brain tissue binned by age. Tg-tau and Tg-ATau values were statistically different from both Tg-con and Tg-A. Two-way ANOVA (F(18, 138) 27.5016,
p 0.0001) revealed a significant effect of age (F(4, 138) 39.077, p 0.0001), genotype (F(3, 138) 68.396, p 0.001), and a significant age*transgene interaction (F(11, 138) 9.661,
p  0.0001), p  0.0001 vs control). C, Kaplan–Meier survival curves showing effect of the overexpression of P301L-tau on premature mortality in Tg-A mice. Despite the
development of substantial pathology in both Tg2576 and rTg4510 mice, neither transgenic line experienced a significant increase in mortality. In control mice (n 69), we detected
an approximate 5% decrease in the population within the first 400 d. This represented an expected minority of mice that died spontaneously or were killed due to colony-associated
ailments or injury. This was also the case in Tg-A and Tg-Tau mice despite the development of A plaque and neurofibrillary tangle pathologies, respectively. In fact, we recorded little
further mortality in these lines as the mice continued to age past 400 d (Tg-A 91% survival at 767 d, n 45, 4 deaths; Tg-Tau 94% survival at 603 d, n 53, 3 deaths). In Tg-ATau
mice, a similar rate of premature death occurred up to the age of230 d (96% survival at 236 d, n 58, 2 deaths). However, after 230 d, we observed a sudden increase in the numbers
of spontaneous deaths such that survival rates decreased to 79% of expected control levels. Interestingly, increased death occurred up to the age of300 d, after which survival rates
plateaued and further loss of Tg-ATau mice was not recorded. Decreased survival between 230 and 300 d was a consistent phenomenon that was observed across multiple
independent cohorts of aging mice and was not provoked by a change in housing conditions. Sex appeared to influence vulnerability to premature death in Tg-ATau mice because
3 females (25%, n 29) and 9 males (75%, n 29) accounted for those found dead in the home cage. Because Tg-ATau mice that lived to be300 d of age had a moribund
phenotype and were extremely inactive, all remaining//mice assigned to the current study were killed at400 d. All genotyped mice in the colony were included in the analysis
(N 251). By log–rank comparison, only Tg-ATau mice differed from all other groups (
3
2  19.629, p 0.0002 vs control).
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findings suggested that A trimers induce tau misfolding
selectively.
Brain levels of A trimers correlate with soluble Alz50-tau in
human tissue
Previously, we reported that apparent A trimers are elevated in
ROS participants with MCI compared with age-matched con-
trols and subjects with AD (Lesne´ et al., 2013). We therefore
examinedwhether the abundance of trimeric A species was cor-
related with the levels of soluble Alz50-tau conformations in
intracellular-enriched fractions of the inferior temporal gyrus of
our MCI cohort (Fig. 2A). We observed that neither soluble mo-
nomeric nor dimeric A levels were related to Alz50-tau levels
(Fig. 2B,C). In contrast, we found a strong positive correlation
Figure4. Age-dependent expressionof solubleA andAPP species in forebrain tissues of bigenic Tg-ATaumice.A, Representative images of solubleAdetected innontransgenic (control),
Tg-A, Tg-Tau, and Tg-ATaumice by immunoprecipitationwith 40/42-end-specific A antibodies and revealed byWestern blot using 6E10.B, Quantitation of the levels of soluble A species
across genotypes revealed an2-fold elevation of A trimers in 3-month-old mice expressing hA compared with younger littermates. No differences were observed between Tg-A and
Tg-ATaumice. Error bars indicate themean SD. Two-way ANOVA (F(3, 26) 106.623, p 0.0001) revealed a significant effect of age (F(1, 26) 305.939, p 0.0001), but no effect of the
genotype (F(1, 26)  1.305, p 0.2651) and no significant age*transgene interaction (F(1, 26)  1.848, p 0.1871) (p 0.05 vs 1-month-old A mice, n 5–7/age/genotype). C,
Representative images of full-length human APP detected in either membrane-enriched (top insert) or intracellular-enriched (bottom insert) fractions of nontransgenic (control), Tg-A, Tg-Tau,
and Tg-ATau mice using 6E10. D, Densitometry analyses revealed an31% accumulation of intracellular APP in 3-month-old Tg-ATau mice compared with age-matched Tg-Amice.
Error bars indicate themean SD. ANOVA (two-way ANOVA, F(3, 26) 13.719, p 0.0001) revealed a significant effect of age (F(1, 26) 16.599, p 0.0001), genotype (F(1, 26) 12.778, p
0.0016), and a significant age*transgene interaction (F(1, 26) 7.358, p 0.0124) (p 0.05 vs 1-month-old A mice, p 0.05 vs 1-month-old A mice, n 5–7/age/genotype).
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(Spearman’s rho 0.464, p 0.0125, n 34) between A trim-
ers measured in extracellular-enriched fractions and soluble
Alz50-tau species (Fig. 2D). This observation suggested that the
findings obtained in vitro could be pathophysiologically relevant
in the context of AD.
Elevated levels of A trimers in young Tg-ATau mice
To attempt to create in vivo experimental conditions in which A
trimers would be elevated and that would allow us to study
the relationship between A and tau, we generated novel Tg-
ATaumicebycrossingTg2576mice (Tg-A)with rTg4510mice
(Tg-Tau). We chose these lines for the following reasons: (1) the
brain tissue of Tg2576mice displays relatively high levels of extracel-
lular A trimers in 1- to 3-month-old transgenic mice (Lesne´ et al.,
2006); (2) both Tg2576 and the CKTTA activator line were in a
129S6 background strain, thereby minimizing genetic background
mixing; (3) plaque deposition and tangle formation occur at 9
months in Tg-A and at4.5months in Tg-Taumice, respectively
(Hsiao et al., 1996; Santacruz et al., 2005), allowing a fairly wide
temporal window to analyze the effects of soluble forms of A and
tau independently of deposited amyloids; and (5) tau-induced neu-
rodegeneration is observed at 5 months of age in Tg-Tau mice,
providing theopportunity to study the interactionof soluble human
A and tau before cell loss (Ramsden et al., 2005). Once lines were
generated, we first assessed whether tissue atrophy in Tg-ATau
mice was altered comparedwith that documented for Tg-Taumice.
Measuringwhole-brainweights revealednoapparentdifferencesbe-
tweenTg-Tau andTg-ATau groups at any of the ages studied (3,
5, 8, 10, and 13 months; Fig. 3A,B). However, survival analyses in-
dicated that Tg-ATaumice displayed enhanced lethality starting
at8monthsof age (Fig. 3C).BecauseTg-Amicedisplay relatively
high levels of extracellularA trimers in3-month-oldmice (Lesne´ et
al., 2006), wemeasured the expression of A and its precursor pro-
tein APP across genotypes at 1 and 3 months of age (Fig. 4). Using
immunoprecipitationswith 40/42-end specific antibodies of A, we
found that brain levels ofAmonomers were similar at both ages
in extracellular-enriched fractions of Tg-A and Tg-ATau
mice (Fig. 4A,B). The abundance of trimers A rose by 2-
fold between at 1 and 3 months in APP-overexpressing mice, a
1.92- and 2.09-fold increase, respectively, in 3-month-old
Tg-A and Tg-ATau brains (Fig. 4B).
Protein expression of full-length human APP pools was as-
sessed in membrane-associated extracts and intracellular-
enriched extracts by Western blotting using 6E10 (Fig. 4C). The
pool of APP bound to membranes was similar between Tg-A
and Tg-ATau mice (Fig. 4C,D). However, we observed a
30.58  7.97% increase in APP levels in intracellular enriched
lysates, whereas actin protein levels used as an internal control
were unchanged (Fig. 4C,D). Similar results were obtained using
aminoterminal (22C11) or carboxyterminal (APPCter-C17) an-
tibodies against APP (data not shown), consistent with an intra-
cellular accumulation of full-length APP.
Rise in A trimers is associated with distinct conformational
tau changes in vivo
Given that brain levels of apparent A trimers increased by 2-fold
without modifying soluble monomeric A levels in 3-month-old
Tg-ATau mice, this experimental condition allowed us to test
Figure 5. Age-dependent expression of tau species in forebrain tissues of bigenic Tg-ATau mice. A, Western blot analyses of soluble tau detected in control, Tg-A, Tg-Tau, and
Tg-ATau mice using CP13, PHF1, Alz50, and Tau5 antibodies displayed apparent changes in Alz50-Tau in brain tissue of bigenic mice. B, Quantitation of the levels of soluble tau
species across genotypes revealed an2.2-fold elevation of Alz-50-positive tau conformers in 3-month-old mice Tg-ATau compared with Tg-Tau mice. Error bars indicate the
mean SD. ANOVA (F Tau5(3, 28) 578.315, p 0.0001; F
CP13
(3, 28) 242.249, p 0.0001; F
PHF1
(3, 28) 156.129, p 0.0001; F
Alz50
(3, 28) 371.269, p 0.0001, respectively)
followed by Student’s t test (p 0.05 vs 3-month-old control mice, p 0.05 vs 3-month-old Tg-A mice,p 0.05 vs 3-month-old Tg-Tau mice, n 5–7/age/genotype).
C, Although no obvious change was observed for CP13-Tau between Tg-Tau and Tg-ATau mice by immunohistochemical analysis, changes in soluble Alz50-tau species within CA1
pyramidal neurons of Tg-ATau mice were obvious at 3 months.
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whether solubleAlz50-taumoleculeswere exclusively augmented in
this environment (Fig. 5). We first compared putative modulations
in tau hyperphosphorylation and conformation observed in the
early or late stages of neurodegenerative disorders involving tau.
Western blotting analyses of intracellular extracts revealed no
changes in CP13-Tau or PHF1-Tau levels between Tg-Tau and Tg-
ATaumice (Fig. 5A,B), indicating that Awas not potentiating
these disease-related tau changes. However, we detected a 2.2-fold
elevation of soluble tau conformers detected with Alz50 in bigenic
Tg-ATau mice compared with Tg-Tau littermates (Fig. 5A,B).
Importantly, total tau levels measured with Tau5 antibodies re-
mained unchanged across Tg-Tau and Tg-ATau mice, suggest-
ing that the conformation of tau was altered in the presence of
constant expression. To support these biochemical analyses of tau,
weperformed immunohistochemical studies onbrain sections from
Tg-A, Tg-Tau and Tg-ATau mice using CP13 and Alz50 anti-
bodies (Fig. 5C). Although CP13-Tau immunoreactivity within the
CA1 hippocampal neurons appeared comparable between Tg-Tau
and Tg-ATau mice (Fig. 5C, top row), a clear increase in Alz50
staining was readily observed in the neuronal soma of CA1 pyrami-
dal neurons of bigenic mice compared with Tg-Tau mice (Fig. 5C,
bottom row). Overall, the 2-fold elevation of A trimers in
3-month-old Tg-ATau mice is associated with a selective 2-
fold increase in taumisfolding.
Twofold elevation in A trimers/Alz50-tau is associated with
selective deficits in KLC1 governing anterograde axonal
transport
Because tau is critical for axonal transport in the presence of
synthetic A oligomers in vitro (Vossel et al., 2010) and APP
appeared to accumulate intracellularly in 3-month-old Tg-
ATaumice, we hypothesized that the accumulation of soluble
Alz50-tau molecules associated with the elevation of A trimers
in bigenic mice could alter the proteins governing anterograde
axonal transport. We therefore assessed the expression levels of
motor proteins responsible for anterograde axonal transport,
KLC-1, KIF-5, and the scaffold protein JIP-1, and for retrograde
axonal transport, dynein. At 1month of age, the abundance of the
measured proteins appeared unaffected (Fig. 6A,B). Two
months later, the expression of KLC-1 was reduced to 65.82 
11.51% in forebrain tissue of Tg-Tau mice compared with non-
transgenicmice. Importantly, KLC-1 expression further dropped
to28% in bigenic Tg-ATau mice, a 2.4-fold decrease com-
pared with Tg-Tau mice (Bonferroni-corrected t test after
ANOVA, p  0.0012, n  5–6/age/genotype). Not all proteins
regulating anterograde axonal transport were impaired because
neither KIF-5 nor JIP-1 protein expression changed across geno-
types. In addition, the brain levels of the motor protein dynein
did not seem to be modified at the ages and genotype tested
(ANOVA, p  0.05, n  5–6/age/genotype). We next assessed
whether KLC-1 expression levels were related to those of Alz50-
tau species in bigenic Tg-ATau mice and found a negative
correlation between these two variables (Fig. 6C). These data
suggest the possibility that the increases in Alz50-tau and A
trimers observed in bigenic Tg-ATau mice might trigger this
change in KLC-1 expression.
To determine whether a similar association was observed in
human brains, we measured KLC-1 protein expression in the
ROS cohort (Fig. 7A). The relative expression of KLC-1 was
reduced in the AD group, consistent with earlier reports (Mo-
Figure 6. Selective lowering of KLC-1 in bigenic Tg-ATau mice. A, B, Western blot analyses of proteins governing axonal transport using brain tissue of nontransgenic (control),
Tg-A, Tg-Tau, and Tg-ATau mice revealed a downregulation of KLC1 in Tg-Tau mice overexpressing human tau, which was enhanced in Tg-ATau bigenic mice (an2.4-fold
potentiation of the effect observed) at 3 months of age. Error bars indicate the mean SD. Two-way ANOVA (F KLC1(7, 49) 16.972, p 0.0001) revealed a significant effect of age
(F KLC1(1, 49) 24.229, p 0.0001), genotype (F
KLC1
(3, 49) 15.256, p 0.0001), and a significant age*transgene interaction (F
KLC1
(3, 49) 14.893, p 0.0001), p 0.05 vs
3-month-old A mice, p 0.05 vs 3-month-old A mice,p 0.05 vs 3-month-old Tau mice, n 5–7/age/genotype). C, Regression analysis between KLC1 protein levels and
soluble Alz50-tau conformers in 3-month-old Tg-ATau (F(1, 5) 24.7712, p 0.0076, n 7).
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rel et al., 2012), and in the MCI group (Fig. 7B). Because
trimeric A levels are highest in MCI subjects from the ROS
cohort (Lesne´ et al., 2013), we examined the relationship be-
tween KLC-1 and Alz50-tau in this group. In this context, the
abundance in KLC-1 protein was inversely correlated with tau
conformers detected by Alz50 (Fig. 7C).
A trimers trigger decreases in KLC-1 protein mediated by
tau conformers
To evaluate directly the potential of A trimers to lower KLC-1
protein levels, we treated mouse cortical neurons with either
brain-derived A trimers (1–2 nM for 60 min) or vehicle and
examined KLC-1 and KIF-5 expression in these cultured primary
cells (Fig. 8A,B). Upon treatment with A trimers, KLC-1 ex-
pression was remarkably reduced to 47.42  5.64% compared
with control neurons (p  0.001, n  6–8/treatment). Consis-
tent with the in vivo findings reported above, no changes in KIF-5
protein expression were observed. Because PrPC and tau have
been proposed tomediate oA-induced toxicity (Roberson et al.,
2007; Laure´n et al., 2009; Vossel et al., 2010; Larson et al., 2012;
Um et al., 2012), we next assessed whether PrPC (Fig. 8C,D) or
tau gene products (Fig. 8E,F) were mediating the lowering of
KLC1 induced by A trimer exposure in Prnp-null orMapt-null
cortical neurons. In agreement with our previous study indicat-
ing that A dimers, but not A trimers, were coimmunoprecipi-
tating with PrPC (Larson et al., 2012), deletion of the gene
encoding for PrPC did not rescue the decrease in KLC-1 proteins
levels whenA trimers were applied to cells (Fig. 8C,D). Similarly
to WT neurons, KIF-5 expression was unaltered in Prnp-null
neurons (Fig. 8D).
To determine whether changes in tau induced by AD brain-
purified A trimers preceded KLC-1 reductions, we applied A
trimers or vehicle onto Mapt-null cortical neurons (Fig. 8E,F).
Contrary to the 50–55% reduction in KLC-1 observed in WT or
Prnp-null neurons, KLC-1 protein levels were unaffected by A
trimers in tau-deficient neurons. This result demonstrated that
A-induced deficits in KLC-1 required expression of tau. Finally,
to establish that soluble Alz50-tau conformers were necessary to
mediate the selective decrease in KLC-1 triggered by trimeric A
application, we preconditioned neurons by delivering Alz50 or
control IgM antibodies intracellularly using Chariot technology
30min before exposure to A trimers (Fig. 8G–I). Intraneuronal
delivery of control immunoglobulins did not alter KLC-1 expres-
sion (Fig. 8G,H), arguing against a possible nonspecific effect of
antibody delivery. When the Chariot shuttling reagent was ap-
plied alone, application of A trimers led to an44% lowering in
KLC-1, similar to what was observed in naive WT neurons (Fig.
8A,B). In contrast, Alz50-pretreated neurons appeared to be pro-
tected from the effect of A trimers on KLC-1 (Fig. 7H). These
findings established directly that Alz50-positive conformers
were required to alter KLC-1 protein levels in the presence of A
trimers.
Discussion
Despite accumulating evidence supporting the concept that oli-
gomeric forms of A constitute the biological vessel responsible
for synaptic dysfunction in AD, the exact role of each assembly of
A remains unknown and shrouded in controversy (Benilova et
al., 2012; Lesne´, 2013). Our group recently suggested that A
molecules identified as AD brain-tissue-purified A dimers and
trimers by immunological, electrophoretic, and liquid-phase
separation techniques activate the kinase Fyn similarly in vitro
(Larson et al., 2012). In the same report, we proposed that the
cellular form of the prion protein PrPC acted as a transducing
receptor for A dimers, but not A trimers, thereby inducing the
hyperphosphorylation of tau at Y18 (Larson et al., 2012). Impor-
tantly, neither soluble A*56 nor protofibrillar As nor A
monomers triggered the phosphorylation of Fyn/tau under sim-
ilar conditions, suggesting that not all A oligomers induce the
same intracellular signaling pathways. This notion is particularly
important in the context of earlier reports demonstrating that the
respective abundance of apparent A dimers, trimers, andA*56
varies across clinical groups in humans (Shankar et al., 2008;
Lesne´ et al., 2013). One likely consequence of these studies is that
each oligomeric A assembly might stimulate distinct cellular
pathways during the course of the disease, all of which (maybe
sequentially or synergistically) constitute the key molecular
events underlying AD.
The hypothesis developed above led us to assess whether ad-
ditional selective pathological changes of tau might occur in pri-
mary cortical neurons exposed to oA species purified from
biologically relevant brain tissue. Surprisingly, we found that sol-
uble Alz50-positive tau conformers were specifically induced
Figure 7. Relationship between KLC-1 and Alz50-tau species in MCI brains. A, Western blot
analysis of KLC-1 protein levels in the ROS cohort analyzed. Actin was used as an internal
standard. The images shownonly correspond to a subset of the specimens studied (12 of 84).B,
Box plot of the relative levels of KLC-1 across clinical groups. Italicized numbers in parentheses
indicate group sizes. No cognitive impairment (“N”) is shown ingreen,MCI is shown inblue, and
AD in indicated by pink boxes. The bar inside the box indicates themedian; the upper and lower
limits of boxes represent the 75 th and 25 th percentiles, respectively; and bars flanking the box
represent the 95 th and fifth percentiles (p 0.05 vs N, Kruskal–Wallis test (
2
2  13.499,
p 0.0012), followedbyMann–WhitneyU test, N 84. C, Regression analyses betweenKLC1
protein levels and soluble Alz50-tau conformers in ROS MCI measured (Spearman’s rho corre-
lation, n 34).
Sherman et al. • Conformers Alter Axonal Transport J. Neurosci., September 14, 2016 • 36(37):9647–9658 • 9655
upon treatment with A trimers. The Alz50 antibody is a mono-
clonal antibody that was initially found to stain fibrillar tau pa-
thology in AD brain tissue (Wolozin et al., 1986; Wolozin and
Davies, 1987). Its epitope was subsequently identified to recog-
nize a folded conformation of tau containing amino acids 2–10
and 312–342 (Carmel et al., 1996; Kopeikina et al., 2013). This
folding change was not detected in cells exposed to other soluble
forms of A tested here (i.e., Amonomers, dimers, A*56, and
A protofibrils). This finding led us to question whether similar
changes could be observed in vivowhenA trimers are abundant.
Based on our prior characterization of the Tg2576 mouse line
(Lesne´ et al., 2006; Lesne´ et al., 2008), we anticipated that crossing
Tg2576with rTg4510mice would allow us to studying a potential
interaction between A trimers and tau pathological changes. In
very young bigenic mice at 3 months of age, in which forebrain
levels of apparent trimeric Awere doubled, we indeed observed
a selective change in tau detected by Alz50. Perhaps not coinci-
dentally, it is interesting to us that the amplitude of the change
in the elevation of A timers between 1- and 3-month-old mice
(a 2.09-fold increase) is similar to the amplitude in the change of
soluble tau conformers detected by Alz50 (a 2.2-fold incr-
ease). In parallel, full-length APP seemed to accumulate in the
intracellular-enriched protein fractions of Tg-ATau mice,
suggesting that APP trafficking might be compromised. Because
synthetic preparations of A oligomers can alter tau-mediated
axonal transport in vitro (Vossel et al., 2010), we tested
whether increases in these soluble forms of A and tau were
associated with modulations in the expression of proteins reg-
ulating axonal transport. Consistent with previous observa-
tions indicating that alterations of fast axonal transport
represent an early pathological event (Stokin et al., 2005;
Muresan and Muresan, 2009), KLC-1 protein levels, which
were already impaired in Tg-Tau brains, were further reduced
in Tg-ATau, whereas KIF-5, JIP-1, and Dynein protein
levels appeared to be unaltered. This observation suggested
that A trimers/Alz50-taumight cooperate in selectively alter-
ing KLC-1-dependent mechanisms. To demonstrate that A
trimers were the initiator molecule in that cascade, we treated
cultured neurons with A trimers purified from AD brain
tissue and validated that neuronal exposure with this oligo-
meric assembly was sufficient to reduce KLC-1 expres-
sion selectively. Although other groups have reported that
uncharacterized synthetic mixtures of A oligomers alter tau-
mediated axonal defects (Vossel et al., 2010), we believe that
our in vitro and in vivo findings are the first to demonstrate
that a specific endogenous oligomeric A assembly alters
proteins governing axonal transport. To our knowledge, this
report also constitutes the first description of selective confor-
mational changes in tau induced by different A oligomers.
Finally, taking into consideration that brain levels of A trim-
ers appear to be highest in subjects with MCI and lower in AD
(Lesne´ et al., 2013), these results highlight the importance of
considering the impact of each A oligomer individually. In-
deed, we predict that a strategy interfering with A trimers/
Alz50-tau would only prevent axonal transport alterations
during the prodromal stage of AD. Based on this current work
and earlier reports suggesting that different oAs trigger dis-
tinct pathological changes during disease progression (Larson
et al., 2012; Lesne´ et al., 2013), we believe that separate thera-
pies aimed at disrupting specific oA/tau interactions will
need to be considered to treat patients at the preclinical AD,
MCI, or AD stages.
Figure 8. Trimeric A-induced selective lowering of KLC-1 is dependent on tau conformers in primary cortical neurons. Mouse primary cortical neurons were exposed to either vehicle or 1 nM
trimeric A for 1 h.A,B, Protein levels of KLC1were altered in cultured neurons after exposurewith A trimers, whereas KIF-5 and actinwere unchanged. Error bars indicate themean SD (t test,
t(7.88) 9.476, p 0.0001,p 0.05 vs vehicle, n 6–8/treatment). C, D, In Prnp-null primary neurons, similar findings were observed to those described in A and B. Error bars indicate the
mean SD (t test (t(8) 9.147, p 0.001),p 0.05 vs vehicle, n 8/treatment). E, F, InMapt-null neurons, KLC1 proteins levels were not downregulated when A trimers were applied to
cells. Error bars indicate the mean SD (t test,p 0.05 vs vehicle, n 6–8/treatment). G–I, Effect of pretreatments with IgM (H ) or Alz50 (I ) delivered using Chariot delivery technology on
KLC1deficits triggeredbyA trimers. Error bars indicate themean SD (t test, t(14)0.548,p0.05,p0.05 vs vehicle,n6–8/treatment; ANOVA, F(3, 25)63.227,p0.0001, followed
by Student’s t test,p 0.05 vs vehicle,p 0.05 vs A 3-mers, n 6–8/treatment for H and I, respectively).
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